Keywords: مهار کننده های تیروزین کیناز; Adverse events; Chronic myeloid leukemia; Survival; Toxicity; Tyrosine kinase inhibitors
مقالات ISI مهار کننده های تیروزین کیناز (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: مهار کننده های تیروزین کیناز; Pulmonary hypertension; Lapatinib; Tyrosine kinase inhibitors
Keywords: مهار کننده های تیروزین کیناز; Signaling pathways; targeted therapy; monoclonal antibodies; tyrosine kinase inhibitors
Case Report: Osimertinib achieved remarkable and sustained disease control in an advanced non-small-cell lung cancer harboring EGFR H773L/V774M mutation complex
Keywords: مهار کننده های تیروزین کیناز; EGFR; Complex mutations; Tyrosine kinase inhibitors; Non-small cell lung cancer; Osimertinib;
Vogt-Koyanagi-Harada disease like presentation in patients with chronic myeloid leukemia
Keywords: مهار کننده های تیروزین کیناز; Chronic myeloid leukemia; Panuveitis; Vogt-Koyanagi-Harada disease; Tyrosine kinase inhibitors; Dasatinib; Imatinib;
How to treat chronic myeloid leukemia (CML) in older adults
Keywords: مهار کننده های تیروزین کیناز; Chronic myeloid leukemia; Geriatric oncology; Targeted therapy; Tyrosine kinase inhibitors; Quality of life;
Coexistence of sensitive and resistant epidermal growth factor receptor (EGFR) mutations in pretreatment non-small cell lung cancer (NSCLC) patients: First or third generation tyrosine kinase inhibitors (TKIs)?
Keywords: مهار کننده های تیروزین کیناز; Non-small cell lung cancer; Tyrosine kinase inhibitors; Osimertinib;
Myeloproliferative neoplasm with ABL1/ETV6 rearrangement mimics chronic myeloid leukemia and responds to tyrosine kinase inhibitors
Keywords: مهار کننده های تیروزین کیناز; Myeloproliferative neoplasm; ABL1-ETV6 rearrangement; Tyrosine kinase inhibitors;
ERBB2 mutation: A promising target in non-squamous cervical cancer
Keywords: مهار کننده های تیروزین کیناز; ICC; invasive cervical cancer; HPV; human papillomavirus; IHC; immunohistochemistry; FISH; fluorescence in situ hybridization; TKIs; tyrosine kinase inhibitors; Cervical cancer; ERBB2 mutation; PIK3CA mutation; KRAS mutation; Targeted therapy;
Variability in lung cancer response to ALK inhibitors cannot be explained by the diversity of ALK fusion variants
Keywords: مهار کننده های تیروزین کیناز; ALK fusion variants; Non-small cell lung cancer; Tyrosine kinase inhibitors; Treatment outcome;
CXCR1 expression predicts benefit from tyrosine kinase inhibitors therapy in patients with metastatic renal cell carcinoma
Keywords: مهار کننده های تیروزین کیناز; Metastatic renal cell carcinoma; CXCR1; Tyrosine kinase inhibitors; Prognosis; Therapeutic response;
Adjuvant Antiangiogenic Agents in Post-nephrectomy Renal Cell Carcinoma: A Systematic Review and Meta-analysis
Keywords: مهار کننده های تیروزین کیناز; Adjuvant chemotherapy; Renal cell carcinoma; Pazopanib; Sunitinib; Sorafenib; Tyrosine kinase inhibitors;
LC-ESI-MS/MS identification and characterization of ponatinib in vivo phase I and phase II metabolites
Keywords: مهار کننده های تیروزین کیناز; Ponatinib; Tyrosine kinase inhibitors; In vivo metabolites; Oxidized cyclic tertiary amine; Phase separation; Sprague Dawley rats;
Targeting FGFR pathway in breast cancer
Keywords: مهار کننده های تیروزین کیناز; Fibroblast growth factor receptor (FGFR); Breast cancer; Tyrosine kinase receptor; Tyrosine kinase inhibitors; FGFR amplification; Multitargeted TKIs; Selective FGFR inhibitors;
Effect of 5,7-dimethoxyflavone on Bcrp1-mediated transport of sorafenib in vitro and in vivo in mice
Keywords: مهار کننده های تیروزین کیناز; TKI; tyrosine kinase inhibitors; BCRP; breast cancer resistance protein; LC/MS/MS; liquid chromatography-tandem mass spectroscopy; MDR; multi-drug resistance; 5,7-DMF; 5,7-dimethoxyflavone; P-gp; P-glycoprotein; EHC; enterohepatic cycling; Tyrosine kinase
Comparable results of autologous and allogeneic haematopoietic stem cell transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia in first complete molecular remission: An analysis by the Acute Leukemia Working Party of the EBMT
Keywords: مهار کننده های تیروزین کیناز; AlloHSCT; AutoHSCT; Ph-positive ALL; Tyrosine kinase inhibitors; Minimal residual disease; GvHD;
Toxicité hépatique des inhibiteurs des tyrosines kinases : mécanismes en cause et conséquences pratiques
Keywords: مهار کننده های تیروزین کیناز; hépatotoxicité; Inhibiteurs des tyrosines kinases; Métabolites réactifs; Recommandations de surveillance; Hepatotoxicity; Tyrosine kinase inhibitors; Reactive metabolites; Monitoring recommendations;
Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door
Keywords: مهار کننده های تیروزین کیناز; Personalised medicine; Targeted therapy; ERBB3; Tyrosine kinase inhibitors; Trastuzumab; Afatinib; Lapatinib;
Anti-cancer Effects of HNHA and Lenvatinib by the Suppression of EMT-Mediated Drug Resistance in Cancer Stem Cells
Keywords: مهار کننده های تیروزین کیناز; ATC; anaplastic thyroid cancer; EMT; epithelial-mesenchymal transition; PTC; papillary thyroid cancer; TKI; tyrosine kinase inhibitors;
Multitargeted kinase inhibitors imatinib, sorafenib and sunitinib perturb energy metabolism and cause cytotoxicity to cultured C2C12 skeletal muscle derived myotubes
Keywords: مهار کننده های تیروزین کیناز; Mitochondria; Complex activities; C2C12 cells; Cytotoxicity; Tyrosine kinase inhibitors; Glucose and nucleoside uptake; BCR; breakpoint cluster region; ABL; Abelson murine leukemia; PDGFR; platelet derived growth factor receptor; VEGFR; vascular endotheli
The role of FLT3 inhibitors as maintenance therapy following hematopoietic stem cell transplant
Keywords: مهار کننده های تیروزین کیناز; Acute myeloid leukemia; FLT3; Hematopoietic stem cell transplant; Tyrosine kinase inhibitors; Multikinase inhibitors; Drug resistance;
Uvéite médicamenteuse et effets indésirables des médicaments en ophtalmologie
Keywords: مهار کننده های تیروزین کیناز; Toxicité oculaire; Effets secondaires; Iatrogénie; Cornée; Kératite; Kératopathies; Uvéites; Rétinopathie; Névrite optique; Anti-TNF; Inhibiteurs des tyrosines kinases; Ocular; Side effects; Toxicity; Drug-induced; Cornea; Keratitis; Kerathopathy;
KRAS-Mutant non-small cell lung cancer: From biology to therapy
Keywords: مهار کننده های تیروزین کیناز; BATTLE; Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination; BET; bromodomains and extra-terminal domain; CDK; cyclin-dependent kinase; Chk1; checkpoint kinase 1; CI; confidence interval; CUSTOM; Molecular Profiling and Targete
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Cell surface receptors and associated signaling pathways)
Keywords: مهار کننده های تیروزین کیناز; Aflibercept; Bevacizumab; Cetuximab; Infection; Pertuzumab; Small-molecule inhibitors; Trastuzumab; Tyrosine kinase inhibitors; VEGF-targeted agents;
Increased Afterload Augments Sunitinib-Induced Cardiotoxicity in an Engineered Cardiac Microtissue Model
Keywords: مهار کننده های تیروزین کیناز; afterload; apoptosis; cardiotoxicity; sunitinib; tissue engineering; toxicology; tyrosine kinase inhibitors; 2D; 2-dimensional; 3D; 3-dimensional; AICAR; 5-aminoimidazole-4-carboxamide 1-β-D-ribofuranoside; AMPK; adenosine monophosphate-activated protein
Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives
Keywords: مهار کننده های تیروزین کیناز; NNSCLC; non-small cell lung cancer; OS; overall survival; EGFR; epidermal growth factor receptor; TKI; tyrosine kinase inhibitor; ALK; Anaplastic lymphoma kinase; MET; mesenchymal epithelial transition factor; PFS; progression free survival; HER2; human e
High throughput routine determination of 17 tyrosine kinase inhibitors by LC-MS/MS
Keywords: مهار کننده های تیروزین کیناز; ALL; Acute Lymphoid Leukemia; CML; Chronic Myeloid Leukaemia; CV; Coefficient of Variation; EGFR; Endothelial derived growth factor Receptor; EMA; European Medicines Agency; ER; Extraction Recovery; FDA; Food and Drug Administration; GIST; Gastro Intestin
Anti-Epidermal Growth Factor Vaccine Antibodies Enhance the Efficacy of Tyrosine Kinase Inhibitors and Delay the Emergence of Resistance in EGFR Mutant Lung Cancer Cells
Keywords: مهار کننده های تیروزین کیناز; EGF; vaccine; resistance; antibody; tyrosine kinase inhibitors; NSCLC;
Interactions between EGFR and PD-1/PD-L1 pathway: Implications for treatment of NSCLC
Keywords: مهار کننده های تیروزین کیناز; Non-small cell lung cancer; Epidermal growth factor receptor; Programmed cell death receptor/ligand 1; tyrosine kinase inhibitors;
Comparative studies on the human serum albumin binding of the clinically approved EGFR inhibitors gefitinib, erlotinib, afatinib, osimertinib and the investigational inhibitor KP2187
Keywords: مهار کننده های تیروزین کیناز; Tyrosine kinase inhibitors; EGFR; Spectrofluorometry; Albumin binding; Binding constants;
Understand the acquired resistance of RTK inhibitors by computational receptor tyrosine kinases network
Keywords: مهار کننده های تیروزین کیناز; Tyrosine kinase inhibitors; Resistance; Protein-protein interaction; Network analysis;
Systematic bioinformatic approaches reveal novel gene expression signatures associated with acquired resistance to EGFR targeted therapy in lung cancer
Keywords: مهار کننده های تیروزین کیناز; DEGs; Differentially Expressed Genes; ES; effect size; EGFR; epidermal Growth Factor Receptor; FDR; False Discovery Rate; GEO; Gene Expression Omnibus; GSEA; Gene Set Enrichment Analysis; IMEx; International Molecular Exchange; MSigDB; Molecular Signature
Development and validation of a sensitive LC-MS/MS method for simultaneous determination of eight tyrosine kinase inhibitors and its application in mice pharmacokinetic studies
Keywords: مهار کننده های تیروزین کیناز; Tyrosine kinase inhibitors; UHPLC-MS/MS; Mice pharmacokinetics;
Allogeneic Stem Cell Transplantation versus Tyrosine Kinase Inhibitors Combined with Chemotherapy in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Keywords: مهار کننده های تیروزین کیناز; Philadelphia chromosome-positive acute lymphoblastic leukemia; Tyrosine kinase inhibitors; Molecular response; Allogeneic stem cell transplantation;
COL5A1 may contribute the metastasis of lung adenocarcinoma
Keywords: مهار کننده های تیروزین کیناز; SCLC; Small-cell Lung Carcinoma; NSCLC; Non-small-cell Lung Carcinoma; TKIs; Tyrosine Kinase Inhibitors; EGFR; Epidermal Growth Factor Receptor; ALK; Anaplastic Lymphoma Kinase; DEGs; Differentially Expressed Genes; GEO; Gene Expression Omnibus; GO; Gene
Concomitance of EGFR mutations and ALK rearrangement in patients with Lung Cancer
Keywords: مهار کننده های تیروزین کیناز; ALK; Anaplastic lymphoma kinase; EGFR; Epithelial growth factor receptor; EML4; Echinoderm Microtubule Associated Protein Like 4; K-Ras; Kirsten rat sarcoma viral; MAPK; Mitogen-activated protein kinases; NSCLCs; Non-small cell lung cancers; PI3K; Phospha
Up-regulation of YPEL1 and YPEL5 and down-regulation of ITGA2 in erlotinib-treated EGFR-mutant non-small cell lung cancer: A bioinformatic analysis
Keywords: مهار کننده های تیروزین کیناز; EGFR; epidermal growth factor receptor; NSCLC; non-small cell lung cancer; TKIs; tyrosine kinase inhibitors; GEO; Gene Expression Omnibus; PPI; protein-protein interaction; DEGs; differentially expressed genes; AXL; AXL Receptor Tyrosine Kinase; ZEB1; zin
The FOXO3-FOXM1 axis: A key cancer drug target and a modulator of cancer drug resistance
Keywords: مهار کننده های تیروزین کیناز; ABCB1; ATP-binding cassette sub-family B member 1; AML; acute myeloid leukaemia; AMPK; adenosine monophosphate-activated protein kinase; ATM; Ataxia-telangiectasia mutated; AURKA; aurora kinase A; BER; base excision repair; Bim; B-cell lymphoma 2 interact
Targeting heme Oxygenase-1 with hybrid compounds to overcome Imatinib resistance in chronic myeloid leukemia cell lines
Keywords: مهار کننده های تیروزین کیناز; HO-1 inhibitors; Tyrosine kinase inhibitors; BCR-ABL; Imatinib; Chronic myeloid leukemia;
Local Therapy for Oligoprogressive Disease in Patients With Advanced Stage Non-small-cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation
Keywords: مهار کننده های تیروزین کیناز; Oligoprogression; Progression-free survival; Radiofrequency ablation; Radiotherapy; Tyrosine kinase inhibitors;
Philadelphia-positive Acute Lymphoblastic Leukemia: Do We Still Need Allogeneic Transplantation? Argument “Pro”
Keywords: مهار کننده های تیروزین کیناز; ALL; Hematopoetic cell transplantation; Minimal residual disease; Philadelphia chromosome; Tyrosine kinase inhibitors;
EGFR-Co-Mutated Advanced NSCLC and Response to EGFR Tyrosine Kinase Inhibitors
Keywords: مهار کننده های تیروزین کیناز; EGFR; Co-mutation; Double mutation; Multiple mutation; Tyrosine kinase inhibitors;
REVIEWBCR-ABL (Ph)-like acute leukemia-Pathogenesis, diagnosis and therapeutic options
Keywords: مهار کننده های تیروزین کیناز; Ph-like ALL; BCR-ABL-like ALL; Kinase-driven ALL; Tyrosine kinase inhibitors; JAK inhibitors;
68Ga labeled Erlotinib: A novel PET probe for imaging EGFR over-expressing tumors
Keywords: مهار کننده های تیروزین کیناز; Erlotinib; Tyrosine Kinase Inhibitors; EGFR; 68Ga; PET imaging; p-NCS-Bn-NOTA; 68Ga-NOTA-Erlotinib;
Tyrosine kinase inhibition is an important factor for gene expression of CRTH2 in human eosinophils and lymphocytes: A novel mechanism for explaining eosinophils recruitment by the neuro-immune axis in allergic rhinitis
Keywords: مهار کننده های تیروزین کیناز; Allergic rhinitis; CRTH2; Late phase reaction; Tyrosine kinase inhibitors; Leukocytes;
Original ArticlePrognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC)
Keywords: مهار کننده های تیروزین کیناز; TP53; EGFR; Non-small cell lung cancer; Survival; Tyrosine kinase inhibitors;
Therapeutic strategies and mechanisms of drug resistance in anaplastic lymphoma kinase (ALK)-rearranged lung cancer
Keywords: مهار کننده های تیروزین کیناز; ALK; Fusion gene; Resistance; Mutation; Tyrosine kinase inhibitor; ALK; Anaplastic lymphoma kinase; TKI; Tyrosine kinase inhibitors; ALCL; Anaplastic large-cell non-Hodgkin's lymphoma; NB; Neuroblastoma; NSCLC; Non-small cell lung cancer; NPM; Nucleophosm
ReviewSBRT for oligoprogressive oncogene addicted NSCLC
Keywords: مهار کننده های تیروزین کیناز; Stereotactic body radiotherapy (SBRT); Oligoprogressive disease (OPD); Oncogene addicted lung cancer; Resistance to targeted therapy; Tyrosine kinase inhibitors; EGFR mutation;
ReviewUncommon EGFR mutations in advanced non-small cell lung cancer
Keywords: مهار کننده های تیروزین کیناز; NSCLC; Uncommon; EGFR mutations; Tyrosine kinase inhibitors;
Biologie moléculaire de la leucémie myéloïde chronique : dernières avancées
Keywords: مهار کننده های تیروزین کیناز; BCR-ABL1; inhibiteurs de tyrosine kinase; Leucémie myéloïde chronique; suivi moléculaire; BCR-ABL1; tyrosine kinase inhibitors; Chronic myeloid leukemia; molecular monitoring;